Lindbrook Capital’s Passage Bio PASG Stock Holding History

Lindbrook Capital’s Portfolio PASG Stock Details PASG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-25	Closed	-$3K	–	2580
2021 Q4	$3K	Buy	+25	New	+$4.08K	﹤0.01%	1688

Other funds holding PASG

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Highline Capital Management New York $53.5M AUM 21.72% 1-Year Est. Return

Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return

Lindbrook Capital's PASG Position: Q1 2022 in Review

Lindbrook Capital sold out of Passage Bio (PASG) in Q1 2022, closing a stake of 25 shares — an estimated $3K sold.

Lindbrook Capital first reported a position in PASG in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 108 funds tracked by Wall St. Rank hold PASG as of Q1 2022.

Lindbrook Capital reported no remaining Passage Bio position as of Q1 2022 after selling out during the quarter.
Lindbrook Capital sold 25 Passage Bio shares in Q1 2022, an estimated $3K.
Lindbrook Capital first reported a position in Passage Bio in Q4 2021 and held it in 1 quarter.
Lindbrook Capital's Passage Bio position peaked at $3K in Q4 2021.
108 funds tracked by Wall St. Rank held Passage Bio as of Q1 2022.

Based on Lindbrook Capital's 13F filing for Q1 2022, filed 21 Apr 2022.